


# The future of mesh repair of POP after the FDA in the Mediterranean



# Conflict of interest

- Consultant for BOSTON SCIENTIFIC
- Partnership with
  - ETHICON
  - SOFRADIM-COVIDIEN
  - COLOPLAST
  - SPIDE MEDICAL
  - ASTELLAS
  - SANOFI
  - ROTTAPHARM
  - ALLERGAN

# Personal experience

➤ Use meshes in vaginal surgery since 1999

➤ Prolene® mesh 1999-2003

de Tayrac R et al., Am J Obstet Gynecol 2002 (Ant repair, 1-year results)

de Tayrac R et al., J Reprod Med 2005 (Ant repair, 2-year results)

de Tayrac R et al., Int Urogynecol J 2006 (Ant repair, 3-year results)

de Tayrac R et al., Int Urogynecol J 2006 (Post repair, 2-year results)

Letouzey V, de Tayrac et al., Eur J Obstet Gynecol 2010 (5-year results)

➤ Soft-Prolene® 2003-2004

Deffieux X, de Tayrac R et al., Int Urogynecol J 2006

➤ Collagen-Coated Mesh (Ugytex®-Pelvitex®-Avaulta®) 2003-2007

de Tayrac R et al., Int Urogynecol J 2006 (Animal study)

de Tayrac R et al., Int Urogynecol J 2006 (Multicentre Study, 230 pts)

Mourtialon P, de Tayrac et al., Int Urogynecol J 2012 (Ant repair, 3-year)

Mourtialon P, de Tayrac et al., Int Urogynecol J 2013 (Post repair, 3-year)

de Tayrac R et al, Int Urogynecol J 2013 (RCT)

➤ Mesh fixed to SS ligaments (Polyform®-Pinnacle®-Uphold®) since 2007

de Tayrac R et al., Int Urogynecol J 2009 (Multicentre study)

Cayrac M et de Tayrac R et al., Int Urogynecol J 2012 (Anatomical study)

de Tayrac R et al., Eur J Obstet Gynecol 2012 (Learning curve)

Rivaux G, de Tayrac R et al., Prog Urol 2012 (Uphold)

Ruzavy Z, de Tayrac R et al., Int Urogynecol J 2013 (voiding function)

➤ ~ 900 cases (50/y 2003-2007 and 100/y 2008-2014)

# 10-year risk of reoperation

17% (underestimated),

risk factors not clearly identified...

but abdominal approach is protective (OR 0.37)

and abdominal approach is protective because of mesh



AUGS PAPERS

www.AJOG.org

## Reoperation 10 years after surgically managed pelvic organ prolapse and urinary incontinence

Mary Anna Denman, MD; W. Thomas Gregory, MD; Sarah H. Boyles, MD, MPH;  
Virginia Smith, MD; S. Renee Edwards, MD; Amanda L. Clark, MD

**OBJECTIVE:** This study measured the 10-year risk of reoperation for surgically treated pelvic organ prolapse and urinary incontinence (POPUI) in a community population.

**STUDY DESIGN:** We conducted a prospective cohort analysis of 374 women who were > 20 years old and who underwent surgery for POPUI in 1995.

**RESULTS:** The 10-year reoperation rate was 17% by Kaplan Meier analysis. Previous POPUI surgery at the time of index surgery conferred a hazard ratio of 1.9 (95% CI, 1.1-3.2;  $P = .018$ ). The abdominal approach was protective against reoperation compared

with the vaginal approach (hazard ratio, 0.37; 95% CI, 0.17-0.83;  $P = .02$ ). With the use of Cox regression, no association was observed for age, vaginal parity, previous hysterectomy, body mass index, prolapse severity, ethnicity, chronic lung disease, smoking, estrogen status, surgical indication, or anatomic compartment.

**CONCLUSION:** A reoperation rate of 17% is unacceptably high and likely represents an underestimate of the true rate. Most of the factors that influence reoperation have not yet been identified.


**Key words:** pelvic organ prolapse, surgery, urinary incontinence

Cite this article as: Denman MA, Gregory WT, Boyles SH, Smith V, Edwards SR, Clark AL. Reoperation 10 years after surgically managed pelvic organ prolapse and urinary incontinence. Am J Obstet Gynecol 2008;198:555.e1-555.e5.

Reoperation risks  
increase  
in recurrent cases  
  
from 14% to 26%


FIGURE 1

### Reoperation risk by surgery status, 1995-2005



A comparison of reoperation rate for subjects with previous POPUI surgery (26%) with the rate for subjects with no previous surgery (14%) at the time of index surgery. Hazard ratio, 1.9; 95% CI, 1.1-3.2;  $P = .02$ .

# NICE and Aberdeen University review 2007



**Systematic review of the efficacy and safety of using mesh or grafts in surgery for anterior and/or posterior vaginal wall prolapse**


Xueli Jia, Cathryn Glazener, Graham Mowatt, Graeme MacLennan, Cynthia Fraser, Jennifer Burr

October 2007

**ReBIP**  
REVIEW BODY FOR  
INTERVENTIONAL  
PROCEDURES

49 studies (including 17 RCTs)  
4569 patients treated  
with/without vaginal mesh/graft

## Recurrence rates




# RCTs

| Authors          | n   | Success with mesh | Success with no mesh | p     |
|------------------|-----|-------------------|----------------------|-------|
| Hiltunen 2007    | 215 | <b>61.5</b>       | <b>93.3</b>          | <.001 |
| N'Guyen 2008     | 76  | <b>55</b>         | <b>89</b>            | <.01  |
| Sivaslioglu 2008 | 90  | <b>72</b>         | <b>91</b>            | .004  |
| Carey 2009       | 139 | <b>65.6</b>       | <b>81</b>            | NS    |
| Altman 2011      | 389 | <b>34.5*</b>      | <b>60.8*</b>         | <.05  |
| de Tayrac 2013   | 162 | <b>64</b>         | <b>89</b>            | <.001 |

*HILTUNEN et al., Obstet Gynecol 2007*  
*N'GUYEN et al., Obstet Gynecol 2008*  
*SIVASLIOGLU et al., Int Urogynecol J 2008*

*CAREY et al., Br J Obstet Gynecol 2009*  
*ALTMAN et al., NEJM 2011*  
*\*Composite criteria (anatomic and functional)*  
*de TAYRAC et al., Int Urogynecol J 2013*

# Long-term efficacy ?



**5 years  
success  
77.8%  
(49/63)**


considering the  
8 patients  
lost to follow-up  
as failure



# Cochrane 2013


## Strong evidence of mesh superiority for anterior repair

- ✓ 40 RCTs
- ✓ Increased risk of recurrent cystocele with traditional repair compared to trans-obturator mesh  
**RR 3.55 (IC95% 2.29-5.51)**
- ✓ No significant difference on functional results, because of mesh-related complications (shrinkage, exposure, pain, dyspareunia)
- ✓ No increased risk of re-intervention




# Our actual indications for synthetic prosthesis

1. Recurrence after previous anterior repair
2. Prolapse of stage  $\geq 3$  ( $> +1$  cm hymen)  
Particularly if both central and lateral defect  
Particularly in active / obese patient
3. Contra-indication for laparoscopic SCP



< 50-60 y.o. • Gold standard = Sacrocolpopexy



> 70-80 y.o. • Decreasing of physical activities  
• Acceptance of pessaries  
• Efficacy of colpocleisis  
• Risk of vaginal erosions increases (vaginal atrophy)  
Multivariate analysis on 138 patients  
with 27 vaginal erosions (20%)  
Patients of > 70 ans  
OR 3,6 [95% CI 1,3-9,7]  $p=0,01$

# Absolute contra-indications for synthetic mesh

- Previous post-op infection with mesh
- Previous pelvic radiotherapy
- Non-equilibrated diabetes
- Long-term steroid use
- Immunodepression
- Chronic hepatitis with ascitis
- Per-op (important) vesical or rectal injury


Risk of  
exposure,  
infection

Risk of  
fistula

# Relative contra-indications for synthetic prosthesis

- Pre-operative sexual activity  
Risk of dyspareunia up to 15%
- Current tobacco use
- Concomittant hysterectomy  
Risk of exposure
- Associated posterior mesh  
Not enough evidence


## HOW TO DECREASE VAGINAL EXPOSURE?



- ✓ Do appropriate training
- ✓ Use only polypropylene monofilament macroporous
  - ✓ Respect strict asepsia
- ✓ Avoid inverted T colpotomy
  - ✓ Use a deep incision
- ✓ Avoid vaginal sulcus perforation
- ✓ Avoid concomitant hysterectomy
  - ✓ Use smaller mesh
  - ✓ Use Lighter mesh

# SURGEON EXPERIENCE

- The learning curve



DWYER et al.  
*Br J Obstet Gynaecol* 2005

- Univariate logistic regression on 198 patients with 14 erosions (7.1%):


Consultant vs fellow

Erosion rates: 2.9% vs 15.6%


OR 0.31 [95% CI 0.09-1.0]  $p=0.06$

ACHTARI, DWYER et al., *Int Urogynecol J* 2005

# Smaller mesh with apical suspension



Exposure rates < 3%



Vu & Goldberg R et al, Int Urogynecol J 2011  
de Tayrac et al., Eur J Obstet Gynecol 2012  
Rivaux, de Tayrac et al., Prog Urol 2012



# Lighter mesh ( $\leq 35$ g/m<sup>2</sup>)

Surg Endosc (2013) 27:231–239  
DOI 10.1007/s00464-012-2425-y



## **Randomized clinical trial of laparoscopic hernia repair comparing titanium-coated lightweight mesh and medium-weight composite mesh**

- ✓ Recent RCT in hernia surgery
- ✓ Light (35g/m<sup>2</sup>, Timesh®) vs medium-weight mesh (75g/m<sup>2</sup>, Parietex®)
- ✓ Decreased post-op pain
- ✓ Return quickly to normal activities
- ✓ With no increased risk of recurrence at 2 years

# The future in 4 points

|                                      |  |
|--------------------------------------|--|
| <b>1. RESPECT INDICATIONS</b>        | <ul style="list-style-type: none"><li>✓ Recurrence after anterior repair or laparoscopic SCP</li><li>✓ Primary high stage anterior or anterior/apical POP</li></ul>  |
| <b>2. RESPECT CONTRA-INDICATIONS</b> | <ul style="list-style-type: none"><li>✓ Women before 50 or after 80 years-old</li><li>✓ Tobacco use</li><li>✓ Previous post-operative infection / radiotherapy</li><li>✓ Non-equilibrated diabetes / long-term steroid use / immunodepression / chronic hepatitis with ascitis</li><li>✓ Intra-operative bladder or rectal injury</li></ul>          |
| <b>3. PREOP PATIENT INFORMATION</b>  | Give a pre-operative honest patient's information on:<br>Risk / Benefit  |
| <b>4. RESPECT SURGICAL RULES</b>     | <ul style="list-style-type: none"><li>✓ Have enough surgical training and experience</li><li>✓ Use only polypropylene monofilament macroporous</li><li>✓ Respect strict asepsia</li><li>✓ Avoid inverted T colpotomy</li><li>✓ Perform a deep incision</li><li>✓ Avoid vaginal sulcus perforation</li><li>✓ Avoid concomitant hysterectomy</li></ul> |